Antibody Fragment Production Breakthrough with 2nd Generation EBA
Richter-Helm BioLogics GmbH & Co. KG announced a technological breakthrough in the field of purification of antibody fragments from an E. coli Expression system. Richter-Helm BioLogics has finalized the downstream process for Phase III clinical trial material using 2nd Generation Expanded Bed Adsorption (EBA) technology developed by the Danish biotech company Upfront Chromatography A/S.
Having conducted a series of tests, Richter-Helm has discovered significant advantages of 2nd Generation EBA over the latest, alternative chromatographic methods. A 60% increase in yield was observed using direct capture. The simplified process is less likely to cause processing problems. The processing time to take product from homogenate to clarified, partially purified material was reduced to one working day, decreasing the possibility of product degradation. The volume of buffers required to perform clarification and capture was reduced significantly, effecting cost of manufacture. According to the company, Upfront’s innovation lay in the usage of higher density adsorbents and the proprietary design of an operational system which provides increased flow rates and is free from clogging and channel formation.
Selection of proprietary mixed mode ligand chemistry enables efficient control of the capture and release of target molecules by simple changes of pH, which can be readily implemented in large-scale production facilities and maintain biological activity of the product. Mixed mode ligands are selected for their suitability for industrial processing, in particular their stability during high temperature cleaning with 1M NaOH, low toxicity, and very low leakage from adsorbent.
Most read news
Topics
Organizations
Other news from the department research and development
Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
In search of the 'holy grail': researchers observe lithium ions in real time - Tracking lithiation with transmission electron microscopy: A decisive step in research on battery materials
Changes to Executive Board of Carl Zeiss AG - Dr. Ludwin Monz will be stepping down from his position as President and CEO of the Executive Board of Carl Zeiss Meditec AG at his own request
Breakthrough in protein research: Toolkit makes protein design faster and more accessible - What used to take weeks can now be completed in a day or less
DNA analysis reveals risk of post-meal insulin resistance - Targeted intervention may be possible
OGT Grants DNA Sequence Variation Licence to Biotype Diagnostics GmbH
New Method for Analysing Nanoporous Materials - Innovative method opens up new possibilities for materials science
A milestone on the pathway to Lab 4.0: A new standard for the smart lab - SPECTARIS presents the first industrial communication standard for laboratory and analytical devices
Fish and seafood - improved trace detection of life-threatening allergy sources - "AQUALLERG-ID": Researchers develop methods for detecting potential food allergens
PerkinElmer appoints President & Chief Operating Officer
ECHA calls for information to avoid unneccessary animal testing
Newly improved NIST reference material targets infant formula analysis